美法仑氟苯达胺联合地塞米松治疗复发难治多发性骨髓瘤的患者报告结局:II期HORIZON研究分析
本文基于关键性II期HORIZON研究(OP-106;NCT02963493),分析64例复发难治多发性骨髓瘤(RRMM)患者接受美法仑氟苯达胺(melflufen)联合地塞米松治疗的患者报告结局。结果显示治疗可维持健康相关生活质量(HRQoL),在总体健康状况/生活质量、躯体功能、情绪功能、疼痛和疲乏等量表上可见具有临床意义的改善,且持续至8个治疗周期后;三重耐药患者(n=50)也呈现类似改善。缓解患者的患者报告结局恶化时间较未缓解患者延迟。
要点
- melflufen联合地塞米松可维持RRMM患者HRQoL并带来临床意义改善
- 总体健康状况/生活质量、躯体功能、情绪功能、疼痛、疲乏等量表均见改善
- 三重耐药患者同样获益,缓解者PRO恶化时间延迟
核心结论
- melflufen联合地塞米松可能随时间维持或改善RRMM患者的HRQoL,包括预后通常较差的三重耐药患者。
- HORIZON试验观察到的临床获益令人鼓舞,并支持将其转化到真实世界实践。
研究设计与样本
- 分析关键性II期HORIZON研究(OP-106;NCT02963493)中RRMM患者(n=64)的患者报告结局。
- 三重耐药疾病患者亚组为n=50。
主要发现
- 治疗在总体健康状况/生活质量、躯体功能、情绪功能、疼痛和疲乏等相关量表上显示具有临床意义的改善,且在8个治疗周期后仍可见。
- 三重耐药疾病患者(n=50)显示类似改善。
- 与未缓解患者相比,缓解患者接受melflufen联合地塞米松治疗后患者报告结局的恶化延迟了相当长的时间。
临床怎么用
- 可将melflufen联合地塞米松作为维持或改善RRMM患者HRQoL的治疗选择之一,包括三重耐药患者。
- 治疗期间关注患者报告结局量表变化,以评估HRQoL获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. Assessment of patient reported-outcome measures from the pivotal, Phase II HORIZON study (OP-106; NCT02963493) in patients with RRMM (n = 64) demonstrated that melphalan flufenamide (melflufen) plus dexamethasone treatment preserved HRQoL. Patients had clinically meaningful improvements, even after eight treatment cycles, in relevant scales such as global health status/QoL, physical functioning, emotional functioning, pain, and fatigue. Patients with triple-class-refractory disease (n = 50) displayed similar improvements. Patient-reported outcome deterioration was delayed for a substantial amount of time in patients who experienced a response to melflufen plus dexamethasone treatment relative to patients who did not experience a response. These findings support the notion that treatment with melflufen plus dexamethasone may sustain or improve HRQoL over time in patients with RRMM, including in patients with triple-class-refractory disease for whom outcomes are generally worse. The clinical benefits observed in patients from the HORIZON trial are encouraging and supportive of translation into real-world practice.
引用
- Larocca A, Leleu X, Touzeau C, et al. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. Br J Haematol. 2021. PMID: 34671975. doi:10.1111/bjh.17887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。